Novavax and Collaborators Make Multiple Presentations at the 9th International Respiratory Syncytial Virus Symposium in South Africa, November 9-13, 2014
Poster, presentation titles, and presenters are listed below:
"Maternal Immunization of Pregnant Baboons with the RSV F Nanoparticle Vaccine Leads to Transplacental Transfer of High Affinity Functional Antibodies in Infants."
Robert C. Welliver, M.D., Professor of Pediatrics and Section Chief, The University of Oklahoma Health Sciences Center
"Placental Transfer of Anti-RSV F Maternal Antibody in Rabbits and Guinea Pigs Immunized with an RSV F Nanoparticle Vaccine Co-administered with Aluminum Phosphate."
Hanxin Lu, Ph.D., Senior Scientist, Novavax, Inc.
"A Phase II Randomized, Observer-blind, Placebo-controlled, Dose-ranging Study to Evaluate the Immunogenicity and Safety of Multiple Formulations of an RSV F Nanoparticle Vaccine with Aluminum, in Healthy Women of Child-bearing Age."
Nigel Thomas, Ph.D., Vice President, Clinical Operations, Novavax, Inc.
"Immunogenicity of the RSV F Nanoparticle Vaccine and Induction of Palivizumab Competing Antibodies: Review of Immunogenicity Data and Consideration of the Clinical Relevance."
Gregory Glenn, M.D., Senior Vice President, Research and Development, Novavax, Inc.
"Cotton Rats Vaccinated with RSV F-Protein Nanoparticle Vaccine are Protected from Infection with RSV Wild Type and Palivizumab Escape Mutant Virus."
Pedro Piedra, M.D., Professor of Molecular Virology and Microbiology, Baylor College of Medicine
RSV is a widespread disease that causes infections of the lower respiratory tract. While RSV affects individuals of all ages, it acutely impacts infants, the elderly, young children and others with compromised immune systems. RSV is the number one cause of hospitalization in infants ages 0 to 12 months in the U.S. and is a significant cause of infant morbidity and mortality globally. Current estimates indicate that RSV is responsible for over 30 million new acute lower respiratory infection episodes and between 150,000 and 200,000 deaths in children under five years old. In the U.S., nearly all children become infected with RSV before they are two years old; it has been associated with 20% of hospitalizations and 15% of office visits for acute respiratory infection in young children.
Barclay A. PhillipsSVP, Chief Financial Officer and Treasurer Novavax, Inc.240-268-2000 David Schullor Andrea Flynn, Ph. D. Russo Partners, LLC212-845-4271 David.email@example.com Andrea.firstname.lastname@example.org